MedPage Today on MSN
Anticoagulant Reversal Drug Pulled From U.S. Market
In May 2018, andexanet was granted accelerated approval as the sole antidote on the market for the DOACs rivaroxaban (Xarelto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback